FDC Limited
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecolo… Read more
FDC Limited - Asset Resilience Ratio
FDC Limited (FDC) has an Asset Resilience Ratio of 15.70% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how FDC Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down FDC Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹364.53 Million | 1.26% |
| Short-term Investments | ₹4.17 Billion | 14.44% |
| Total Liquid Assets | ₹4.53 Billion | 15.70% |
Asset Resilience Insights
- Good Liquidity Position: FDC Limited maintains a healthy 15.70% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
FDC Limited Industry Peers by Asset Resilience Ratio
Compare FDC Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for FDC Limited (2007–2025)
The table below shows the annual Asset Resilience Ratio data for FDC Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 17.86% | ₹4.85 Billion | ₹27.14 Billion | -0.37pp |
| 2024-03-31 | 18.23% | ₹4.50 Billion | ₹24.68 Billion | -1.41pp |
| 2023-03-31 | 19.64% | ₹4.60 Billion | ₹23.43 Billion | -2.74pp |
| 2022-03-31 | 22.38% | ₹5.08 Billion | ₹22.70 Billion | -4.53pp |
| 2021-03-31 | 26.91% | ₹5.26 Billion | ₹19.56 Billion | -0.83pp |
| 2020-03-31 | 27.75% | ₹5.03 Billion | ₹18.13 Billion | +2.77pp |
| 2019-03-31 | 24.98% | ₹4.10 Billion | ₹16.40 Billion | -2.25pp |
| 2018-03-31 | 27.22% | ₹4.09 Billion | ₹15.04 Billion | -2.73pp |
| 2017-03-31 | 29.96% | ₹4.37 Billion | ₹14.57 Billion | +9.12pp |
| 2016-03-31 | 20.83% | ₹2.57 Billion | ₹12.34 Billion | -2.89pp |
| 2015-03-31 | 23.73% | ₹2.73 Billion | ₹11.49 Billion | +1.32pp |
| 2014-03-31 | 22.40% | ₹2.37 Billion | ₹10.56 Billion | +1.45pp |
| 2013-03-31 | 20.95% | ₹2.02 Billion | ₹9.66 Billion | -11.21pp |
| 2012-03-31 | 32.16% | ₹2.78 Billion | ₹8.63 Billion | +24.10pp |
| 2011-03-31 | 8.07% | ₹621.02 Million | ₹7.70 Billion | +5.02pp |
| 2010-03-31 | 3.05% | ₹207.29 Million | ₹6.79 Billion | -0.82pp |
| 2009-03-31 | 3.88% | ₹211.52 Million | ₹5.46 Billion | -1.49pp |
| 2008-03-31 | 5.36% | ₹267.31 Million | ₹4.98 Billion | -7.10pp |
| 2007-03-31 | 12.47% | ₹516.86 Million | ₹4.15 Billion | -- |